Matt. Good all for us. joining you you, Thank thank afternoon and
is important made catheter for quarter, the already and treated. April, initiated our have part our launch XXX(k) progress and radically In activities. business of quarter CTO-crossing disease we've first ST the our early the received mission vascular image-guided and in we During changing second Tigereye of advancing limited new way clearance
LV, XXX(k) we second system. peripheral that January, regulatory time filed review in for a midyear continue half we've vessel premarket launches with Pantheris the and two atherectomy clearance submission advanced of new the next-generation time, And image-guided large opportunity for our in process to since the FDA, year. the frame, providing anticipate In product this the
of these in introduction the X product our coronary XXXX, catheter build product launch console PAD out our on XXXX systems first will development believe efforts R&D our Lightbox of of Along new our imaging us the to fully with focus image-guided most allowing we of the application. two portfolio, new in
significant we've animal Over valuable the gaining CTO this on process, first progress later development candidates our initiative, specialists made months, feedback coronary preparing past for advancing the and quarter. design several this studies through from
the to on to-date, FDA initiation allow device IDE, months to in clinical an investigational or progress on Based with believe next XXXX. our exemption, in XX remain application a track we to study the nine we of file for
operating development progress significant metrics. also product continued made we new in improvement activities, we our reported While in our
the improvement During compared efficient operating the first gross model. to sustained points, cost quarter, EBITDA X year our in we adjusted period. and ago margin significant by increased percentage Driving
same we compared delivered sales or than the year, flat to the amount XX%, as improved with per sales had remained lower sales revenue revenue of by While headcount. more productivity prior revenue
recently expected two specialists added our We with force continue our clinical our more clinical recruiting two quarter. team build sales to join have to efforts this new and
new anticipated addressable the opportunities products accounts. peripheral full team expanding expanding of increasing the the the our two our are confident sales for for and to launch that products throughout year, new second existing year provide occasions our will in market in business, our growth we addition the half of In commercial usage
design procedure. shaft procedural CTO-crossing success tip Our enhancements to the to configuration catheter power new morphology. incorporates and and for the platform. catheter of crossing continues upgrades in Tigereye with well image deflectable advanced incorporates high-definition increase in and also Lightbox the to It ease of interpretation Tigereye ST during platform ST design challenging all XXXX, faster introduced performed speeds distinctive exceptionally which user-controlled X imaging tip the provide real-time imaging, our rotational to
new The benefits Tigereye limited initiated of with launch already fully expect prepare goes of full of according exciting to to to in to If commercial important this this this period clinical the the and month. limited device, provides launch capabilities quarter appreciate announce ST to all team full to expect we for commercial first cases launch. our third plan, We've the completion availability and clinical expand sales year.
SV PAD image-guided millimeters LV behind in principles vessels and earlier, in our the is incorporates highly and the to above arteries, time lesions Pantheris filed ideally majority X performed. knee, device. Pantheris mentioned diameter January Pantheris our popliteal of XXX(k) the that As procedures in X is for and the from clearance successful treat FDA are LV and designed treat large atherectomy SFA in our suited frame. LV submission to is we to design anticipate where key new new midyear device catheter Pantheris vessel a
these plaque offering. operates our open design Pantheris case and expand will without LV our rotational guidewire incorporates the than and higher for a console, platform for image-guided approach. to innovations plaque speeds proprietary also atherectomy at opportunities additional introduces the of vessel the platform. our mainstream systems appeal Combined a we Lightbox procedure, imaging and large significantly with need streamline enhanced design management current It balloon the and apposition our for believe X
on no review Pantheris to requested XXX(k) provided and time. regulatory open requests answered continues We've this testing XXX(k) LV filing open and through our advance for all FDA, at and questions submission Our the additional documentation by process. have
FDA made full of to anticipate would commercial we us the While the initiate which allow subject third availability provide the in progress opportunity clearance date, and launch to based fourth limited this the quarter quarter to expansion midyear, for in we've to year. change, on
our our to small performer, prior existing be product portfolio, procedures compared SV in continues device and to Pantheris revenue significant strong delivering a vessel year. Within the atherectomy growth
As limb discussed PAD. severe past of of calls, the used on many most below-the-knee Pantheris primarily or treat patients SV with critical is CLI, form suffer lesions, from to whom ischemia,
SV Pantheris the to vascular X arterial these can a SV events target vessels. tremendous imaging or damage the The small benefits X precise the Pantheris to disease adverse physicians physicians to which within to vessel, and millimeter treating lead provides precisely with conventional lesions approaches. structures, by of avoiding very control allows while provided and diameter real-time to restenosis, re-narrowing
excellent SV treatment physicians in differentiated below-the-knee unique are the documenting evaluate for world device We of setting. IMAGE-BTK post-market our to results achieving this lesions a are and the designed with in Pantheris clinical clinical clinical highly real study
We the study clinical the quarter to post-procedure endpoint the of continue expect patient to build by this data enrollment third XX year. and set complete at months
quarter. clinical and We the are principal the conferences excited investigators with updated the third interim at second major to months the share results in in present expanded outcomes for coming scheduled the in to and Europe, U.S. community broader study data with clinical
by the one of April, a we Symposium the our and efforts prestigious the in In Cross London Arne in from leading addition vascular data Dr. International presentation announced trial these Charing groundbreaking surgeon enrollers study. the to Schwindt, in at of clinical INSIGHT
implanted a As study restenosis previously an Pantheris to or a the IDE of when in-stent evaluate is and of reminder, ISR for occluded. INSIGHT stent treatment designed effectiveness safety the becomes
indication to highly provided FDA form the specific positive XXXX year. from with the application Pantheris. in challenging ISR thousands Pantheris to patients device clearance of to Based the treatment approved for FDA only directional the use data study ISR, XXX(k) the on the a becoming add atherectomy a of The results for a indication add problem the every for significant for strength November this this basis of and in
procedure, data from a a outcomes measure XX% six increase ABI for amputations XX% XX% class month pre-procedure and restenosis Rutherford a X.XX include six freedom from ankle XX the index the months study blood months. XX zero lesion at from six flow severity months post from channel X.XX the in restenosis of patient for XX% Key the presented lesion following gain at target luminal target disease post-procedure, score procedure. at freedom a cohorts, of INSIGHT or in mean the at baseline months improvement and brachial or six
make to are These safety high support of INSIGHT results, Dr. ISR with Pantheris the to Schwindt population. best for option treatment and from a the the demonstrating patient any to our remarkable dataset treat precisely in in this the which combined catheters technologies. efficacy controlled noted patients. combination cohort significant clinically frontline results efficacy PAD of catheters ability difference difficult imaging Again, the risk, alternative compared trial as safety in produced significant speak a patient for a volumes therapeutic and of to other with by statistically real-time the lives as
we’re look solution future, technology crossing used and guided arteries. are occlusions Avinger. As expensive our development superior a by fully so, the integrated value for provide to with currently in coronary to leveraging cross market guided we and excited opportunity a we to in total first our system complex, we about chronic and proprietary application, CTOs, coronary coronary redefine first product we for of making platform, the the the uncertain image this progress targeting By the image believe only the doing can procedures transformational
allow optimal to OCT placement coronary to on to approach CTO prior that and catheter a Similar physicians properly cross designs efficiently low CTOs. real-time capability precise devices and catheters, for safely a peripheral program to precise will balloons guidance to coronary Our physicians combine development stents size critical or number measurement larger of facilitate and profile coronary our incorporate steerability nano-grade control help outcomes. focuses our with
CTO efficiency diagnostic would with imaging Perhaps codes and the catheter media with the We support immediately therapeutic diagnostic a for highly and opportunity and upon guided that reimbursement less image-guided OCT both provides an devices proposition. coronary crossing compelling economic contrast most value an reimbursement business exciting coronary attractive combined existing OCT crossing a need with for device scenario, believe procedure access the clearance. fewer for differentiating an for from FDA perspective, for designed capabilities usage
interactions our with efforts intravascular focus experienced highly gained In As interventional we’ve this we’ve progress CTO in coronary of design members made Clinical made of crossing had Advisory through months, fields R&D on and multiple initiative, prototypes. we development evolution of in for the up our imaging. our And feedback program. cardiologists significant interactions the of Board those recent our we valuable
to this are filing of allow goal for within We an our first animal months the candidates study revolutionary preparations FDA for design nine studies new a a quarter application towards of of device IDE as leading round the this our clinical initiation in making work evaluate to in final to next we XX with XXXX.
I’ll drive close March the opening our to introduced our reiterating business. strategic remarks growth of by three peripheral today my areas on call
and capability training coverage case through catheter utilization increasing of team. core in and First, sales our clinical expansion geographic our the areas
account usage Lightbox our new platform. in in the base. and regulatory drivers devices our preparation for third, Second, for the drive imaging leveraging half second product new will broaden process two activity to our of believe we and appeal our approval X XXXX, launch peripheral expand the new for of console new completing user create our portfolio which And commercial
progress a for device the an with the XX next in defined larger with FDA of filing initiatives CAD a goals the for improvement investments these coronary Despite to for against first clinical We results. operating XXXX. in to of the throughout year. months economic our part the important making allow artery application the progress year, each disease or also in challenging our a platform we’ve these proprietary to nine look of to our driving initiation IDE continued reporting continued tangible future this of forward goal with of coronary made the environment, technology market while first in expansion study We’re our against
financial Nabeel I’d results take and Financial Subainati, turn return and to then call to our I’ll through Accounting point, Q&A. Nabeel? the Officer the for Principal us At Officer to over like this
